Nov 11, 2026

Why Medical Affairs and Brand Plans Fall Out of Alignment and How to Realign Them at the Source

Why do medical affairs plans and brand plans drift apart, even after they’ve been finalized? We look at the challenges facing brand and medical affairs planning in pharma, and why alignment has to start with shared insight rather than shared documents. 

The brand plan has been circulated. All functions have reviewed it, the comments have been resolved, and the document is signed off. Everyone agrees. 

Six months later, the commercial team is telling one story, and the medical affairs team another. Neither has gone rogue. Each is doing exactly what it understood the plan to ask of it. 

When this happens, the instinct is to blame communication, or to schedule an extra alignment meeting. Because we work across medical affairs and commercial brand planning, we see both sides, and the cause usually sits further upstream. Most organizations are good at aligning their plans. Far fewer align the underpinning assumptions and thinking those plans are built on. 

That gap has always existed. What has changed is its cost. Competitive fields are more crowded, external pressure is rising, and teams are expected to decide faster with an expanding body of information to weigh. Medical affairs and brand teams have less room than ever to plan from different pictures.  

More information, diverging interpretations 

The split starts long before a plan is on paper. Market research, real-world data, competitor intelligence, advisory board feedback, and field force insight arrive continuously, in varied formats, scattered across functions. 

Yet more data hasn’t brought more clarity. Without a shared synthesis, each function draws conclusions from its own slice. Medical affairs teams read the evidence one way, brand teams read the market another, and both can be right. That is why the disconnect is so easy to miss: nobody is wrong, so nobody raises a flag. 

The hard part is distillation: deciding together what truly matters to the brand and setting aside what doesn’t. 

The AI-informed customer 

The risk of divergence increases as the customer’s information environment changes. Growing numbers of healthcare professionals (HCPs) use AI tools to form a view of a disease area or treatment before and between interactions with a pharma company. Every plan now rests on an assumption about what those customers already know, what they are likely to conclude from it, and where the company can add something AI can’t. If medical affairs and brand teams make different assumptions here, they are effectively planning for different market scenarios. 

Alignment that arrives too late 

In many organizations, medical affairs and commercial teams still plan in silos. The brand plan is developed largely within the commercial team, then passed to medical affairs and other functions to “align.” By the time it reaches them, the defining decisions have been made: which patients to prioritize, which evidence gaps to address, where the brand will compete. What remains is a review. Medical affairs’ input can shape the detail, but the direction is already set. 

The outcome is a plan that has been approved but not owned, and a plan that isn’t owned tends to buckle the first time it is tested. 

A global pharmaceutical company we work with recognized this pattern and set out to change it. Where commercial leads previously drafted the brand plan alone and then circulated it, the company now invests in developing the plan collaboratively from the outset to create alignment and buy-in. 

Why the gap goes undetected 

Even when both teams start from the same view, it rarely stays that way for long. Plans are typically produced once a year, but the beliefs underneath them can shift within months as competitors read out and new data lands. Each team absorbs the news on its own timetable. Many plans have become exhaustive documents written for the approval meeting and seldom reopened by the cross-functional team afterward. A plan too heavy to consult can’t guide the decisions that follow, so they get made without it. And when the two strategies slip out of step, there is no common reference point to reveal it. 

Separate tactics, one strategy 

None of this is an argument for dissolving the line between medical affairs and commercial. That line exists for good reason, and tactics need firm guardrails. 

Over time, though, the separation that activities need has often extended to thinking as well. Separate tactics have drifted into separate strategies, each based on its own reading of the same patients and the same market. 

That isn’t how customers experience it. An HCP who speaks to a medical science liaison this week and a sales representative the next isn’t dealing with two organizations. They are forming one view of one company, with one story and one level of credibility. When the strategies behind those conversations pull apart, the HCP is often the first to notice. The result is a confused market and diluted credibility.  

The guardrails belong at the point of execution. The overall product and portfolio strategy must be integrated, and so does the understanding beneath it. 

Align the thinking first: the integrated insight foundation 

Because the gap emerges before either plan is drafted, alignment must begin there too. Both the brand plan and the medical affairs plan should be built from a shared, cross-functional set of insights and assumptions that remains the reference point for decisions long after sign-off. We describe this as an integrated insight foundation. 

In practice, this means medical affairs, commercial, and other key functions, such as market access, bring their expertise together to agree on the fundamentals.  

We find it helps to structure this around four questions: 

  • What is true today about the patient, the evidence, the competition, and what customers already believe?  
  • What could shift, and which triggers would change the landscape if they happened?  
  • Where can the company make a meaningful contribution?  
  • And therefore, which strategic choices will the cross-functional team align behind?  

Every discipline then plans its activities from that common ground. 

This is the transition from parallel planning to integrated product planning, and it redefines alignment. Instead of negotiating over a finished document, teams debate the substance while it can still shape the strategy. Disagreements come out early, when they are useful. And when the market evolves, there is one set of beliefs to revisit, not two plans to reconcile. 

A simple test of where you stand: ask your medical affairs and brand leads, independently, to name the three things most likely to determine the product’s success over the year ahead. If their answers differ, so do your plans, whatever the sign-off says. 

Where the series heads from here 

An integrated insight foundation gives medical affairs and brand the same north star. But the customer and the landscape are both moving. So how does a plan keep pace, and where does human expertise matter most? 

In the second article, we explore how medical affairs and brand teams can keep a future-proofed and well-built plan: light enough to use, pressure-tested against the signals that would change it, and clear about where the company can make a meaningful contribution as the market evolves. In the third, we turn to AI, examining where it genuinely widens the strategic choices in front of a team before it commits, and why human judgment, informed by benchmarking, must still make the final call. 

Contact us

Whether you're exploring a new opportunity or looking for strategic support, we’d love to hear from you.
Find out more
Contact us

Latest Resources

Explore our latest insights, whitepapers, and event highlights to learn more about the latest developments and perspectives shaping the evolving healthcare landscape.

View all

Get in Touch

Reach out to explore how we can
support your goals

If you're interested in learning more about our services or would like to speak with the team, please get in touch.

Contact us